Xindou Biotechnology

Xindou Biotechnology is a Shanghai-based biopharmaceutical company specializing in the field of targeted protein degradation (TPD). The company focuses on the development of molecular glues and PROTACs (Proteolysis-targeting chimeras) to address "undruggable" targets in oncology and immunology. By leveraging its proprietary discovery platform, Xindou aims to identify novel small molecule degraders with high specificity and therapeutic potential. The firm was founded in 2021 by industry experts with extensive experience in drug discovery and medicinal chemistry. Xindou has successfully raised significant venture capital from prominent investors such as Sequoia China and Matrix Partners China. Currently, the company is advancing a pipeline of pre-clinical candidates through lead optimization and IND-enabling studies.